Detalhe da pesquisa
1.
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Breast Cancer Res
; 22(1): 124, 2020 11 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33176887
2.
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Breast Cancer Res
; 21(1): 69, 2019 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-31126332
3.
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer.
JNCI Cancer Spectr
; 7(2)2023 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36806942
4.
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.
Clin Cancer Res
; 26(1): 35-45, 2020 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31597662
5.
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.
Nat Commun
; 9(1): 3501, 2018 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-30158526